HeartBeam (BEAT) Stock Overview
Operates as a medical technology company that focuses on developing and commercializing electrocardiogram solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
BEAT Community Fair Values
Create NarrativeSee what 9 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
HeartBeam, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.49 |
| 52 Week High | US$4.00 |
| 52 Week Low | US$0.47 |
| Beta | -0.79 |
| 1 Month Change | -11.39% |
| 3 Month Change | -43.85% |
| 1 Year Change | -55.15% |
| 3 Year Change | -74.96% |
| 5 Year Change | n/a |
| Change since IPO | -89.48% |
Recent News & Updates
BEAT: Funding Runway Extension Will Support Commercial Execution And Future Upside Potential
Analysts have reset their HeartBeam price expectations lower, with the average target moving from about $8 to about $5 as they factor in a slower than previously modeled revenue ramp, modestly softer margin assumptions, some dilution from the recent $11.5m equity raise at $0.80 per share, and new coverage that still frames the stock as a higher risk and higher P/E opportunity within its space. Analyst Commentary on HeartBeam Recent Street research on HeartBeam highlights a mix of caution on execution timing and continued interest in the stock's long term potential.
BEAT: Slower Commercial Ramp And Dilution Will Set Up Future Rebound
Analysts now place their average price target for HeartBeam closer to $2.00 from $2.50, reflecting expectations for a slower pace of revenue scaling and potential dilution effects, even as recent research updates continue to describe the Q1 progress and funding runway in constructive terms. Analyst Commentary Recent Street commentary around HeartBeam has shifted toward a more cautious tone, with several bearish analysts recalibrating expectations on revenue timing, funding effects, and the risk that execution may lag earlier assumptions.Recent updates
BEAT: Funding Runway Extension Will Support Commercial Execution And Future Upside Potential
Analysts have reset their HeartBeam price expectations lower, with the average target moving from about $8 to about $5 as they factor in a slower than previously modeled revenue ramp, modestly softer margin assumptions, some dilution from the recent $11.5m equity raise at $0.80 per share, and new coverage that still frames the stock as a higher risk and higher P/E opportunity within its space. Analyst Commentary on HeartBeam Recent Street research on HeartBeam highlights a mix of caution on execution timing and continued interest in the stock's long term potential.BEAT: Slower Commercial Ramp And Dilution Will Set Up Future Rebound
Analysts now place their average price target for HeartBeam closer to $2.00 from $2.50, reflecting expectations for a slower pace of revenue scaling and potential dilution effects, even as recent research updates continue to describe the Q1 progress and funding runway in constructive terms. Analyst Commentary Recent Street commentary around HeartBeam has shifted toward a more cautious tone, with several bearish analysts recalibrating expectations on revenue timing, funding effects, and the risk that execution may lag earlier assumptions.BEAT: Slower Commercial Ramp Will Set Up Future Rebound After Recent Dilution
HeartBeam's updated analyst price target has shifted from $4.00 to $2.50 as analysts factor in expectations for a slower revenue ramp, modestly adjusted profit margins, and a higher future P/E, partly influenced by recent equity dilution and revised sales timelines following the Q1 update. Analyst Commentary Recent Street research on HeartBeam points to a more cautious tone, with several bearish analysts recalibrating their expectations after the Q1 update.
BEAT: Extended Funding Runway Will Support Longer Commercialization Ramp
HeartBeam's updated analyst price targets, which have shifted lower from prior levels such as $8 to $5 and $5.50 to $2.50, reflect analysts' expectations for a longer revenue ramp and the impact of recent equity dilution on fair value and profit margin assumptions. Analyst Commentary Recent Street research on HeartBeam presents a mixed picture, with analysts balancing expectations for a slower revenue ramp and share dilution against a constructive view on the company’s longer term execution potential.Concierge Cardiac Care And AI Collaboration Will Shape A Long Term Bullish View
Catalysts About HeartBeam HeartBeam develops portable, cable free 12 lead ECG technology for at home and ambulatory cardiac assessment. What are the underlying business or industry changes driving this perspective?At Home ECG Clearances And AI Pipeline Will Transform Cardiac Care Over Time
Catalysts About HeartBeam HeartBeam develops portable, cable free ECG technology that lets patients capture clinical grade 12 lead readings at home or on demand. What are the underlying business or industry changes driving this perspective?Home Cardiac Diagnostics And AI Delays Will Restrain Progress Yet Eventually Support Potential Upside
Catalysts About HeartBeam HeartBeam develops a portable, cable free ECG system intended to give patients at home clinical grade 12 lead readings supported by remote cardiologist review. What are the underlying business or industry changes driving this perspective?Here's Why We're Watching HeartBeam's (NASDAQ:BEAT) Cash Burn Situation
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...Companies Like HeartBeam (NASDAQ:BEAT) Could Be Quite Risky
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...HeartBeam gets a new chief medical officer
HeartBeam (NASDAQ:BEAT) appoints renowned Stanford cardiologist Peter J. Fitzgerald, MD, PhD, as Chief Medical Officer. Dr. Fitzgerald is the Director of the Center for Cardiovascular Technology and Director of the Cardiovascular Core Analysis Laboratory at Stanford University Medical School. He has also been a consultant to the US Food and Drug Administration for the past 20 years, focused on medical technology and data driven health analytics. Shares are up 2.37% premarket.HeartBeam gets patent to enable generation of its credit card-sized ECG, shares rise ~15%
HeartBeam (NASDAQ:BEAT) on Wednesday said it had been issued a patent from the U.S. Patent and Trademark Office which enables it to generate its credit card-sized AIMIGo 12-lead electrocardiogram (ECG) for the detection of heart attacks. Shares of the company rose 14.5% to $3.08 in early trading. “This patent provides additional intellectual property protection for our breakthrough AIMIGo technology offering 12-lead ECG capability in the form of a credit card-sized device with the same footprint as the single-lead products currently in the market today,” BEAT CEO Branislav Vajdic said in a statement. The newly issued patent - No. 11,445,963 B2 - expands on BEAT's granted and pending core patents for remote heart attack detection, the company said.HeartBeam surges 54% on U.S. patent for ECG patch monitor to detect heart attacks
HeartBeam (NASDAQ:BEAT) is trading 54% higher premarket after it received patent for a 12-lead electrocardiogram (ECG) patch monitor to detect acute coronary syndrome and cardiac arrhythmia by the United States Patent and Trademark Office. The company expects its ECG device to detect ACS diagnosis including myocardial infarction (heart attack) and angina. The newly issued patent expands on the HeartBeam’s previously granted US patent for a 12-lead ECG patch monitor technology. The patch patent follows HeartBeam’s already granted core patents for remote detection of heart attacks. Stock has been down ~66% YTD.Shareholder Returns
| BEAT | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -1.2% | -1.2% | -2.1% |
| 1Y | -55.2% | -12.8% | 18.8% |
Return vs Industry: BEAT underperformed the US Medical Equipment industry which returned -12.8% over the past year.
Return vs Market: BEAT underperformed the US Market which returned 18.8% over the past year.
Price Volatility
| BEAT volatility | |
|---|---|
| BEAT Average Weekly Movement | 11.6% |
| Medical Equipment Industry Average Movement | 8.4% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: BEAT's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: BEAT's weekly volatility has decreased from 21% to 12% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 16 | n/a | www.heartbeam.com |
HeartBeam, Inc. operates as a medical technology company that focuses on developing and commercializing electrocardiogram solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility. The company develops HeartBeam System, a cable-free and ambulatory 12L ECG that captures the heart’s electrical signals from three dimensions for high-fidelity data collection and advanced diagnostics for arrhythmia assessment which consists of credit card sized 3D ECG recording device, a patient application, a physician portal, and powerful cloud-based algorithms. HeartBeam, Inc. was incorporated in 2015 and is based in Santa Clara, California.
HeartBeam, Inc. Fundamentals Summary
| BEAT fundamental statistics | |
|---|---|
| Market cap | US$26.95m |
| Earnings (TTM) | -US$20.30m |
| Revenue (TTM) | n/a |
Is BEAT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BEAT income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$20.30m |
| Earnings | -US$20.30m |
Last Reported Earnings
Jun 30, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.36 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did BEAT perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/08/21 23:24 |
| End of Day Share Price | 2026/08/21 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
HeartBeam, Inc. is covered by 5 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Benjamin Haynor | Alliance Global Partners |
| William Sutherland | Benchmark Company |
| Anderson Schock | B. Riley Securities, Inc. |